Mayo Acute Stroke Trial for Enhancing Recovery (MASTER)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
James F. Meschia, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00805792
First received: December 9, 2008
Last updated: October 4, 2012
Last verified: October 2012
  Purpose

This study involves treating patients that have suffered an acute ischemic stroke with the medication donepezil (Aricept ®). The hypothesis is that taking donepezil (FDA-approved for the treatment of Alzheimer's Disease) for the first 90 days following a stroke enhances recovery.


Condition Intervention Phase
Ischemic Stroke
Drug: Donepezil
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Mayo Acute Stroke Trial for Enhancing Recovery

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Percent of Participants With National Institutes of Health Stroke Scale (NIHSS) Score = 0 or 1 at Day 90 [ Time Frame: 90 days post-stroke ] [ Designated as safety issue: No ]
    The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient).


Secondary Outcome Measures:
  • Change in Mean National Institutes of Health Stroke Scale (NIHSS) Score at 90 Days Post-stroke [ Time Frame: baseline, 90 days post-stroke ] [ Designated as safety issue: No ]
    The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient).

  • Change in Mean Barthel Index of Activities of Daily Living Score at 90 Days Post-stroke [ Time Frame: baseline, 90 days post-stroke ] [ Designated as safety issue: No ]
    The Barthel Index of Activities of Daily Living (ADLs) measures functional disability by quantifying patient performance in 10 activities of daily life. These activities can be grouped according to self-care (feeding, grooming, bathing, dressing, bowel and bladder care, and toilet use) and mobility (ambulation, transfers, and stair climbing). 5-point increments are used in scoring, with a maximal score of 100 indicating that a patient is fully independent in physical functioning, and a lowest score of 0 representing a totally dependent bed-ridden state.

  • Change in Mean Score on Mini Mental State Exam at 90 Days Post-stroke [ Time Frame: baseline, 90 days post-stroke ] [ Designated as safety issue: No ]
    The mini-mental state examination (MMSE) is a 30-point questionnaire test that is used to screen for cognitive impairment. The questionnaire samples functions including arithmetic, memory and orientation to time and place. Scores range from 0 to 30. Any score greater than or equal to 25 points is effectively normal (intact). Below this, scores can indicate severe (≤9 points), moderate (10-20 points) or mild (21-24 points) cognitive impairment.

  • Change in Time to Complete Neuropsychological Trail Making Tests A and B at 90 Days Post-stroke [ Time Frame: baseline, 90 days post-stroke ] [ Designated as safety issue: No ]
    The Trail-making test consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy. It can provide information about visual search speed, scanning, speed of processing, mental flexibility, as well as executive functioning. There are two parts to the test: A, in which the targets are all numbers (1,2,3, etc.)and the test taker needs to connect them in sequential order, and B, in which the subject alternates between numbers and letters (1, A, 2, B, etc.).


Enrollment: 33
Study Start Date: November 2008
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Donepezil
Participants received treatment with donepezil within 24 hours after the onset of ischemic stroke symptoms. Participants received donepezil 5 mg/day for 30 days, followed by an increase to 10 mg/day for 60 days.
Drug: Donepezil
Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
Other Name: Aricept

Detailed Description:

We hypothesize that donepezil (5 mg per day, titrated up to 10 mg per day as tolerated) will enhance recovery following stroke by improving attention, learning and memory thereby enhancing rehabilitation. The null hypothesis is that the probability of a favorable outcome among post-stroke donepezil users is equal to that observed among similar participants in an existing National Institutes of Neurological Disorders and Stroke (NINDS) resource, the Phase III clinical trial of Tissue Plasminogen Activator (tPA) for acute ischemic stroke. The NINDS tPA stroke trial has been used as historical control data in pilot trials of reperfusion and neuroprotection.

The MASTER trial will be a multicenter, single-arm NINDS Recominant tPA trial-controlled, modified 2-stage adaptive clinical trial set in 2 tertiary care hospitals in the United States. Participants will be men and women with acute (< 24 hours of onset of symptoms) ischemic stroke. A favorable outcome will be defined as National Institutes of Health Stroke Scale (NIHSS) values of 0 or 1 at 90 days post-stroke.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Definite or probable acute ischemic cerebrovascular syndrome (AICS), as defined by Kidwell et al (Stroke. 2003;34:2995-8).
  • Experimental treatment started within 24 hours of onset of symptoms.
  • Age ≥ 18 years.
  • Ability and willingness to return for follow-up visits.
  • Willingness of an available informant who knows the patient well to participate in informant-based questionnaires for the duration of the follow-up period.
  • Living in independent or semi-independent living situation before the stroke.
  • Fluent in English before the stroke.
  • Provides written informed consent.
  • Near visual acuity of at least 20/200 in at least one eye.
  • Auditory acuity of at least having the ability to detect finger rubbing in at least one ear.

Exclusion Criteria:

  • Parkinson's disease or restless leg syndrome.
  • Partial or generalized seizures.
  • No acute decompensated heart failure
  • Routinely requiring daytime supplemental oxygen before the stroke; study participants on continuous positive air pressure (CPAP) for obstructive sleep apnea remain eligible.
  • Gastrointestinal or genitourinary surgery within 1 month of screening.
  • Gastrointestinal bleeding.
  • Syncope or symptomatic bradycardia.
  • Creatinine ≥ 3.5 mg/dL or requiring dialysis.
  • Peptic ulcer disease.
  • Asthma.
  • Tracheostomy or endotracheal intubation.
  • Taking donepezil or other acetylcholinesterase inhibitor at screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00805792

Locations
United States, Florida
Mayo Clinic
Jacksonville, Florida, United States, 32224
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: James F. Meschia, M.D. Mayo Clinic
  More Information

Additional Information:
Publications:
Responsible Party: James F. Meschia, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00805792     History of Changes
Other Study ID Numbers: 08-005098
Study First Received: December 9, 2008
Results First Received: July 17, 2012
Last Updated: October 4, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
Ischemic stroke
treatment
recovery
donepezil
Aricept

Additional relevant MeSH terms:
Stroke
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Brain Infarction
Brain Ischemia
Donepezil
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on September 18, 2014